Kura Oncology, Inc. (NASDAQ:KURA) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET
Company Participants
Patti Bank – IR
Troy Wilson – President and CEO
Mollie Leoni – CMO
Tom Doyle – SVP of Finance and Accounting
Brian Powl – CCO
Conference Call Participants
Li Watsek – Cantor Fitzgerald
Yen-Der Li – Leerink Partners
Jason Zemansky – Bank of America
Peter Lawson – Barclays
Dara Azar – Stifel
Charles Zhu – LifeSci Capital
David Dai – UBS
Justin Zelin – BTIG
George Farmer – Scotiabank
Operator
Good day, everyone, and welcome to today’s Q4 2024 Kura Oncology, Inc. Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note this call is being recorded. It is now my pleasure to turn the conference over to Patti Bank, Investor Relations. Please go ahead.
Patti Bank
Thank you, Angela. Good afternoon, and welcome to Kura Oncology’s fourth quarter and full year 2024 conference call. Joining me on the call are Dr. Troy Wilson, President and Chief Executive Officer; Dr. Mollie Leoni, Chief Medical Officer; Brian Powl, Chief Commercial Officer; and Tom Doyle, Senior Vice President of Finance and Accounting.
Before I turn the call over to Dr. Wilson, I’d like to remind you that today’s call will include forward-looking statements based on current expectations. Such statements represent management’s judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from expected results. Please refer to Kura’s filings with the SEC, which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the company.
With that, I’ll turn the call over to Troy.
Troy Wilson
Read the full article here